Work

Outcomes in patients with liver or lung metastatic castration-resistant prostate cancer (mCRPC) treated with the androgen receptor inhibitor enzalutamide: Results from the phase III AFFIRM trial.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.5065

Authors: Yohann Loriot, Karim Fizazi, Johann Sebastian De Bono, David Forer, Mohammad Hirmand, Howard I. Scher

Institutions: Institut Gustave Roussy, Université Paris-Sud, Royal Marsden NHS Foundation Trust, Institute of Cancer Research, Medivation, Inc. (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2605272107

Cites:

Cited by: 18

Related to: 10